MAVS and metabolic dysfunction-associated steatotic liver disease: We also analyzed MAVS expression in a public data set (GEO accessions GSE135251), which provides bulk RNA sequencing results from samples of 206 patients with MASLD at various fibrosis stages and 10 healthy liver controls.17 The analysis indicated that the MAVS mRNA is significantly upregulated in the liver of people with both MASLD and MASH at different stages (MASH F1–F4) (Figures 2D, E).